R
Ricardo Tamez
Researcher at Bristol-Myers Squibb
Publications - 9
Citations - 941
Ricardo Tamez is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Entecavir & Hepatitis B. The author has an hindex of 6, co-authored 8 publications receiving 890 citations.
Papers
More filters
Journal ArticleDOI
Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B
Ting-Tsung Chang,Ching-Lung Lai,Seung Kew Yoon,Samuel S. Lee,Henrique Sérgio Moraes Coelho,Flair José Carrilho,Fred Poordad,Waldemar Halota,Yves Horsmans,Naoky Tsai,Hui Zhang,Daniel J. Tenney,Ricardo Tamez,Uchenna H. Iloeje +13 more
TL;DR: Extended therapy with entecavir through 5 years maintained or increased rates of HBV DNA suppression and ALT normalization and the safety profile of entecvir was consistent with previous reports.
Journal ArticleDOI
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Robert G. Gish,Ting-Tsung Chang,Ching-Lung Lai,R. De Man,Adrián Gadano,Fred Poordad,Joanna Yang,Helena Brett-Smith,Ricardo Tamez +8 more
TL;DR: In this paper, the authors describe the characteristics of nucleoside-naive hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B, who achieved hepatitis B surface antigen (HBsAg) loss during entecavir or lamivudine therapy.
Journal ArticleDOI
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Eugene R. Schiff,Halis Simsek,William M. Lee,You Chen Chao,Sette H,Harry L.A. Janssen,Steven Han,Zachary Goodman,Joanna Yang,Helena Brett-Smith,Ricardo Tamez +10 more
TL;DR: It is confirmed that the performance of entecavir relative to that of lamivudine in patients with advanced liver fibrosis/cirrhosis was consistent with the relationship observed in the overall treated population.
Journal ArticleDOI
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
Daniel Shouval,Ching-Lung Lai,Ting-Tsung Chang,Hugo Cheinquer,Paul Martin,Giampiero Carosi,Steven Han,Sabahattin Kaymakoglu,Ricardo Tamez,Joanna Yang,Daniel J. Tenney,Helena Brett-Smith +11 more
TL;DR: The majority of protocol-defined Responders relapsed after 1 year when treatment was discontinued, and treatment with entecavir beyond 1 year provided continued virological and biochemical benefit.
Journal ArticleDOI
Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Ting-Tsung Chang,You-Chen Chao,V. V. Gorbakov,Kwang Hyub Han,Robert G. Gish,R. De Man,Hugo Cheinquer,Fernando Bessone,Helena Brett-Smith,Ricardo Tamez +9 more
TL;DR: For responders who discontinued therapy (per protocol), 24‐week off‐treatment evaluation is presented to provide a more ‘complete picture’ of what clinicians can expect when treating nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B.